Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

This study is testing a combination of immunotherapy (an anti-PD-1 drug) and chemotherapy given before surgery (called neoadjuvant treatment) in patients with locally advanced oral cavity squamous cell carcinoma — a type of mouth cancer — to shrink the tumor before removal. **You may be eligible if...** - You have been diagnosed with oral squamous cell carcinoma (mouth cancer) confirmed by biopsy - Your cancer is locally advanced (stage T1-2N1-2M0 or T3-4aN0-2M0) and is potentially curable by surgery - There is no evidence of spread to distant parts of the body - Your blood counts, liver function, and other organ measurements meet required levels **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have poor organ function - Other health or prior treatment criteria apply Talk to your doctor to see if this trial is right for you.